Qtern

Active Ingredient(s): Dapagliflozin + Saxagliptin
FDA Approved: * February 27, 2017
Pharm Company: * ASTRAZENECA AB
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Qtern Overview

Dapagliflozin (INN,[2] USAN,[3] trade name Farxiga /frsi/ far-SEE-g in the U.S. and Forxiga in the EU and Russia) is a drug of the gliflozin class, used to treat type 2 diabetes. It was developed by Bristol-Myers Squibb in partnership with AstraZeneca. Contents 1 Medical uses 2 Side effects 3 Mechanism of action 3.1 Selectivity 4 Research 5 References 6 External links Medical uses In July 2011 a U.S. Food and Drug Administration (FDA) endocrinologic and metabolic drugs advisory...

Read more Qtern Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Dapagliflozin

Recent Qtern Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Dapagliflozin + Saxagliptin
  • Tablet: 10mg + 5mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Drugs with one or more similar ingredients: (9 results)





Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2017 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 20 August 2017.

We are committed to your privacy.

Copyright © 2005-2017 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.